These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Incidence and prognostic value of cytomegalovirus-specific antibodies of the IgM class in kidney transplant recipients].
    Author: Eichler C, Kaden J, May G.
    Journal: Z Urol Nephrol; 1990 Aug; 83(8):425-9. PubMed ID: 2173294.
    Abstract:
    In a retrospective study of 326 patients which have been received a renal allograft between 1985 and 1988 at the Berlin Kidney Transplant Centre, all recipients were divided into 3 groups according to their antibody status against cytomegalovirus (IgM+/IgG+; IgM-/IgG+; IgM-/IgG-). Frequency and severity of CMV infections in the early period after kidney transplantation have been compared. Primary infections could be observed in 51/112 (45.5%) patients (group 3), secondary infections in 60/190 (31.6%) patients (group 2). In 7.4% of all recipients (24/326) CMV-specific IgM antibodies could be found at the time of transplantation (group 1). In primary infections the patients have had a significantly higher frequency of moderate or severe CMV diseases as in secondary infections (24.4 vs. 8.3%). In group 3 this frequency was 16.7%. In conclusion, it is not necessary to select renal allograft recipients according their positive CMV-IgM-antibody status, but a close-meshed posttransplant control is indicated.
    [Abstract] [Full Text] [Related] [New Search]